Organon & Co. Common Stock vs Silicon Motion Technology Corporation American Depositary Shares — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Silicon Motion Technology Corporation American Depositary Shares trades at $221 (market cap $8.36B). The key difference: Silicon Motion Technology Corporation American Depositary Shares is far larger — about 2.3× Organon & Co. Common Stock's market cap, and Silicon Motion Technology Corporation American Depositary Shares pays the higher dividend (0.81%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Silicon Motion Technology Corporation American Depositary Shares for 0 Days on average.
| OGN | SIMO | |
|---|---|---|
Market Cap | $3.62B | $8.36B |
Volume | 2,892,999 | 663,682 |
Sector | Health | Technology |
52-Week High | $13.81 | $336.90 |
52-Week Low | $5.70 | $80.16 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $11.04B | $8.35B |
Dividend Yield | 0.58% | 0.81% |
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Silicon Motion (SIMO) trades at $246.63, down 0.13% on the day, with technical indicators showing neutral signals. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $2.43 versus $2.13, and revenue growth projected to reach $1.3B in 2026. Analyst sentiment remains overwhelmingly positive with 81% buy ratings and a consensus price target of $356.25, representing 44% upside potential from current levels.
The outlook for SIMO appears favorable given accelerating enterprise storage demand and AI infrastructure expansion. Key risks include semiconductor cycle volatility and competitive pressures in NAND controllers. With robust profitability metrics including 31.6% ROE and expanding margins, the stock offers growth exposure to the AI storage market, though investors should monitor execution on Q3 2026 earnings expectations of $3.3 EPS.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →Silicon Motion Technology Corporation designs and develops NAND flash controllers for solid-state storage, with flagship SSD, eMMC, and UFS controller products, including its Ferri-branded automotive and industrial storage solutions, used by OEMs and NAND flash makers worldwide.
Read more on SIMO →